
浏览全部资源
扫码关注微信
400042 重庆,第三军医大学大坪医院野战外科研究所消化内科
[陈东风, E-mail: chendf1981@126.com Chen Dongfeng, E-mail: chendf1981@126.com
收稿:2017-01-06,
修回:2017-03-08,
纸质出版:2017-06-30
移动端阅览
秦谦, 龚豪, 杨洋, 等. 粪菌移植通过改善肠黏膜屏障功能治疗硫酸葡聚糖诱导的小鼠结肠炎[J]. 第三军医大学学报, 2017,39(12):1231-1238.
Qian Qin, Hao Gong, Yang Yang, et al. Fecal microbiota transplantation alleviates dextran sodium sulfate-induced colitis in mice by modulating intestinal mucosal barrier function[J]. Journal of Third Military Medical University, 2017, 39(12): 1231-1238.
秦谦, 龚豪, 杨洋, 等. 粪菌移植通过改善肠黏膜屏障功能治疗硫酸葡聚糖诱导的小鼠结肠炎[J]. 第三军医大学学报, 2017,39(12):1231-1238. DOI: 10.16016/j.1000-5404.201701032.
Qian Qin, Hao Gong, Yang Yang, et al. Fecal microbiota transplantation alleviates dextran sodium sulfate-induced colitis in mice by modulating intestinal mucosal barrier function[J]. Journal of Third Military Medical University, 2017, 39(12): 1231-1238. DOI: 10.16016/j.1000-5404.201701032.
目的
2
研究粪菌移植(fecal microbiota transplantation,FMT)对硫酸葡聚糖(dextran sulfate sodium,DSS)诱导的溃疡性结肠炎小鼠的治疗作用。
方法
2
将92只7周龄雌性C57BL/6小鼠,按照随机数字表法分为4组,每组23只:对照组正常饮水,模型组饮用2% DSS 7 d,在第8天时换成不含DSS的灭菌纯净水饮用7 d,FMT预防组在饮用DSS建模的同时给予FMT灌胃处理,FMT治疗组在饮用7dDSS模型建成后进行FMT灌胃处理7 d。记录各组小鼠体质量变化和疾病活动度,并收集每日粪便进行肠道菌群分析。在第7、14天末分别处死10只小鼠,采集血液标本进行TNF-α和D-乳酸测量,留取结肠组织分别进行HE染色、透射电镜观察
免疫组化染色检测紧密连接相关蛋白ZO-1和Occludin的表达。
结果
2
FMT治疗组小鼠体质量、疾病活动程度和结肠长度较DSS诱导结肠炎小鼠模型组显著改善(
P
<
0.01)。FMT治疗组血清D-乳酸和TNF-α水平较模型组明显降低(
P
<
0.05
0.01)。透射电镜可见FMT治疗组结肠上皮的损害及细胞间紧密连接结构和上皮完整性较模型组显著改善。FMT治疗及预防处理后ZO-1和Occludin的表达较模型组明显增高(
P
<
0.05
P
<
0.01)。FMT预防及治疗都能显著改善DSS引起的肠道菌群改变,促进乳杆菌属增殖而抑制拟杆菌属和颤螺菌属的生长。
结论
2
FMT预防及治疗都能显著改善硫酸葡聚糖引起的肠道菌群改变,促进乳杆菌属增殖而抑制拟杆菌属和颤螺菌属的生长。
Objective
2
To assess the therapeutic effect of fecal microbiota transplantation (FMT) on dextran sodium sulfate (DSS)-induced ulcerative colitis (UC) in mice.
Methods
2
Atotal of 92 female C57BL/6 mice (7 weeks old) were randomized into 4 equal groups
namely the normal control group (fed with normal water)
DSS treatment group (model group
fed with 2% DSS solution for 7dfollowed by sterilized distilled water for another 7 d)
preventive FMT group (fed with 2% DSS solution with intragastric FMT administration for 7 d)
and therapeutic FMT group (fed with 2% DSS solution for 7dfollowed by intragastric FMT administration for another 7 d). The changes in body weight and disease activity index (DAI) of the mice were recorded
and fecal samples were collected daily for 16S rRNA analysis. Ten mice from each group were sacrificed at days 7 and 14 for detection of serum levels of tumor necrosis factor-α (TNF-α) and D-lactate and pathological examination of the colon with HE staining and transmission electron microscopy. Immunohistochemistry was employed to detect the expression of ZO-1 and Occludin in the colon.
Results
2
Compared with the mice in the model group
the mice receiving therapeutic FMT showed significant improvements in body weight
DAI score and colon length (
P
<
0.01) and obviously lowered serum levels of TNF-α (
P
<
0.05) and D-lactate (
P
<
0.01) with alleviated colonic epithelial damage and improved tight junction (TJ) and intestinal epithelial integrity. Preventive and therapeutic FMT both resulted in markedly increased expression levels of ZO-1 and Occludin in the colon compared with those in the model group (
P
<
0.05
0.01)
ameliorated the DSS-induced alteration of intestinal flora
promoted the proliferation of
Lactobacillus
and inhibited the growth of
Bacteroides
and
Oscillosporic
in the colon.
Conclusion
2
FMT for both preventive and therapeutic purposes ameliorates the altera
tion of intestinal flora induced by DSS
promotes the proliferation of
Lactobacillus
and inhibits the growth of
Bacteroides
and
Oscillosporia
in the intestines of mice.
Bouma G, Strober W. The immunological and genetic basis of inflammatory bowel disease[J]. Nat Rev Immunol, 2003, 3(7): 521-533. DOI: 10.1038/nri1132.
Chi K R. Epidemiology: Risingin the East[J]. Nature, 2016, 540(7634): S100-S102. DOI: 10.1038/540S100a.
Lepage P, Hasler R, Spehlmann M E, et al . Twin study indica tes loss of interaction between microbiota and mucosa of patients with ulcerative colitis[J ] . Gastroenterology, 2011, 141(1): 227-236. DOI: 10.1053/j.gastro.2011.04.011.
Moayyedi P, Surette M G, Kim P T, et al . Fecal microbiota transplantation induces remission in patients with active ulcerative colitis in a randomized controlled trial[J ] . Gastroenterology, 2015, 149(1): 102-109.e6. DOI: 10.1053/ j.gastro.2015.04.001.
Li M, Liang P, Li Z, et al . Fecal microbiota transplantation and bacterial consortium transplantation have comparable effects on the re-establishment of mucosal barrier function in mice with intestinal dysbiosis[J ] . Front Microbiol, 2015, 6: 692. DOI: 10.3389/fmicb.2015.00692.
Wirtz S, Neufert C, Weigmann B, et al . Chemically induced mouse models of intestinal inflammation[J ] . Nat Protoc, 2007, 2(3): 541-546. DOI: 10.1038/nprot.2007.41
[Ma https://html.publish.founderss.cn/rc-pub/api/common/picture?pictureId=99253565&type=middle https://html.publish.founderss.cn/rc-pub/api/common/picture?pictureId=99253565&type= https://html.publish.founderss.cn/rc-pub/api/common/picture?pictureId=99253565&type=small opolska M, Fol M. Intestinal microbiota transplantation for the treatment of Clostridium difficile infection[J ] . Med Dosw Mikrobiol, 2015, 67(3/4):207-219.
Siegel C A, Whitman C B, Spiegel B M, et al . Development of an index to define overall disease severity in IBD[J ] . Gut, 2016. DOI: 10.1136/gutjnl-2016-312648.
Turner J R. Molecular basis of epithelial barrier regulation: from basic mechanisms to clinical application[J]. Am J Pathol, 2006, 169(6): 1901-1909. DOI: 10.2353/ajpath.2006.060681.
Turner J R. Intestinal mucosal barrier function in health and disease[J]. Nat Rev Immunol, 2009, 9(11): 799-809. DOI: 10.1038/nri2653.
Curro D, Ianiro G, Pecere S, et al . Probiotics, fibre and herbal medicinal products for functional and inflammatory bowel disorders[J ] . Br J Pharmacol, 2016. DOI: 10.1111/ bph.13632.
Joyce S A, Macsharry J, Casey P G, et al . Regulation of host weight gain and lipid metabolism by bacterial bile acid modification in the gut[J ] . Proc Natl A cad Sci U S A, 2014, 111(20): 7421-7426. DOI: 10.1073/pnas.1323599111.
Braat H, van den Brande J, van Tol E, et al . Lactobacillus rhamnosus induces peripheral hyporesponsiveness in stimulated CD4 + T cells via modulation ofdendritic cell function[J ] . Am J Clin Nutr, 2004, 80(6): 1618-1625..
Tiequn B, Guanqun C, Shuo Z. Therapeutic effects of Lactobacillus in treating irritable bowel syndrome: a meta-analysis[J]. Intern Med, 2015, 54(3): 243-249. DOI:10.2169/internalmedicine.54.2710.
Lucke K, Miehlke S, Jacobs E, et al . Prevalence of Bacteroides and Prevotella spp. in ulcerative colitis[J ] . J Med Microbiol, 2006, 55(Pt 5): 617-624. DOI:10.1099/ jmm.0.46198-0.
Wexler H M. Bacteroides: the good, the bad, and the nitty-gritty[J]. Clin Microbiol Rev, 2007, 20(4): 593-621. DOI:10.1128/CMR.00008-07.
Yu L, Zhai Q, Tian F, et al . Potential of lactobacillus plantarum CCFM639 in protecting against aluminum toxicity mediated by intestinal barrier function and oxidative stress[J ] . Nutrients, 2016, 8(12). DOI: 10.3390/ nu8120783.
Llopis M, Antolin M, Guarner F, et al . Mucosal colonisation with Lactobacillus casei mitigates barrier injury induced by exposure to trinitronbenzene sulphonic acid[J ] . Gut, 2005, 54(7): 955-959. DOI: 10.1136/gut.2004.056101.
Zhang X, Zhao Y, Xu J, et al . Modulation of gut microbiota by berberine and metformin during the treatment of high-fat diet-induced obesity in rats[J ] . Sci Rep, 2015, 5: 14405. DOI: 10.1038/srep14405.
Kelly C J, Zheng L, Campbell E L, et al . Crosstalk between microbiota-derived short-chain fatty acids and intestinal epithelial HIF augments tissue barrier function[J ] . Cell Host Microbe, 2015, 17(5): 662-671. DOI: 10.1016/j. chom.2015.03.005.
Konikoff T, Gophna U. Oscillospira: a central, Enigmatic component of the human gut microbiota[J]. Trends Microbiol, 2016, 24(7): 523-524. DOI: 10.1016/ j.tim.2016.02.015.
0
浏览量
0
下载量
0
CSCD
关联资源
相关文章
相关作者
相关机构
京公网安备11010802024621